SLI

SLI handeln
2.212,64 PKT -3,09 PKT -0,14 %
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

WKN A0QZBF

ISIN CH0030252883


Analysen zu SLI-Werten

Datum Rating Analyst
25.01.05 Novartis Outperform Goldman Sachs
24.01.05 Novartis Overweight Prudential Securities
24.01.05 Richemont Outperform Goldman Sachs
24.01.05 Holcim Neutral Sarasin Research
25.01.05 Novartis Neutral Sarasin Research
24.01.05 Richemont Neutral Merrill Lynch
24.01.05 Novartis Neutral Sarasin Research
21.01.05 Roche Buy Sarasin Research
21.01.05 Logitech Accumulate Helvea
21.01.05 Richemont Buy Sarasin Research
24.01.05 Novartis Neutral HypoVereinsbank
21.01.05 Holcim Accumulate Helvea
24.01.05 Straumann Outperform Credit Suisse First Boston
21.01.05 Richemont Accumulate Helvea
21.01.05 Novartis Kaufen Helaba Trust
24.01.05 Lonza Reduce Sarasin Research
21.01.05 ABB (Asea Brown Boveri) Neutral Sarasin Research
21.01.05 Richemont Buy Sarasin Research
24.01.05 Novartis Kaufen Hamburger Sparkasse
21.01.05 Zurich Insurance Buy Sarasin Research
24.01.05 ABB (Asea Brown Boveri) Kaufen NATIONAL-BANK
21.01.05 Zurich Insurance Accumulate Helvea
20.01.05 Swiss Life Buy M.M. Warburg
20.01.05 Logitech Buy Sarasin Research
20.01.05 Zurich Insurance Buy Sarasin Research
20.01.05 Holcim Halten Helaba Trust
20.01.05 Novartis Hold SEB
20.01.05 Logitech Buy Sarasin Research
20.01.05 UBS Buy Sarasin Research
20.01.05 Richemont Outperform Goldman Sachs
20.01.05 Holcim Neutral Sarasin Research
20.01.05 Novartis Akkumulieren Independent Research
21.01.05 Logitech Accumulate Helvea
20.01.05 Lindt Underperform Goldman Sachs
21.01.05 Holcim Accumulate Helvea
20.01.05 Novartis Neutral Sarasin Research
21.01.05 Lindt Neutral Sarasin Research
21.01.05 Novartis Buy Helvea
19.01.05 Novartis Equal-weight Morgan Stanley
19.01.05 Givaudan Neutral Sarasin Research